Prometheus Biosciences

Merck still scouting for M&A deals, even after $10.8B takeover of Prometheus
Merck still scouting for M&A deals, even after $10.8B takeover of Prometheus
Fierce Pharma
Merck
Prometheus Biosciences
M&A
Flag link:
Biotech M&A is picking back up - here are the latest deals
Biotech M&A is picking back up - here are the latest deals
BioPharma Dive
Novartis
Chinook Therapeutics
Paratek
Sobi
CTI BioPharma
Astellas
Iveric Bio
Assertio Holdings
Spectrum Pharmaceuticals
Merck
Prometheus Biosciences
Pfizer
Seagen
Sanofi
Provention Bio
Sun Pharma
Concert Pharmaceuticals
BioNTech
InstaDeep
AstraXeneca
CinCor Pharma
Ipsen
Albireo
Chiesi
Amryt
Moderna Therapeutics
OriCiro Genomics
Flag link:
Heightened US antitrust fears rattle biopharma
Heightened US antitrust fears rattle biopharma
EP Vantage
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Flag link:
Merck bets big on PRA023 with $10.8bn Prometheus acquisition offer
Merck bets big on PRA023 with $10.8bn Prometheus acquisition offer
Clinical Trials Arena
Merck
Prometheus Biosciences
PRA023
ulcerative colitis
Flag link:
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Merck
Prometheus Biosciences
M&A
AbbVie
Bristol Myers Squibb
Flag link:
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Big Pharmas finally strike with GSK, Merck acquisitions, signaling accelerating pace of M&A
Fierce Pharma
Big Pharma
M&A
Merck
Prometheus Biosciences
GSK
Bellus Health
Flag link:
Merck’s latest deal turns up the spotlight on immune system drugmakers
Merck’s latest deal turns up the spotlight on immune system drugmakers
BioPharma Dive
Merck
M&A
Prometheus Biosciences
immunology
Flag link:
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
Merck to buy inflammatory disease drugmaker Prometheus for $10.8B
BioPharma Dive
Merck
M&A
Prometheus Biosciences
IBD
Flag link:
Big caps bounce back for biopharma
Big caps bounce back for biopharma
EP Vantage
pharma stocks
Amgen
BeiGene
Bristol Myers Squibb
Gilead Sciences
Lantheus Holdings
Madrigal Pharmaceuticals
Merck
Moderna Therapeutics
Novo Nordisk
Prometheus Biosciences
Roche
Flag link:
Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's
Prometheus Biosciences Catapults 176% On Promising Results In UC and Crohn's
Investors Business Daily
Prometheus Biosciences
clinical trials
ulcerative colitis
Crohn’s disease
Flag link:
Pfizer hands another asset to Roivant
Pfizer hands another asset to Roivant
EP Vantage
Pfizer
Roivant
RVT-3101
PF-06480605
Prometheus Biosciences
Flag link:
Can This Tiny Biotech Take On Pfizer?
Can This Tiny Biotech Take On Pfizer?
Motley Fool
Prometheus Biosciences
Pfizer
inflammatory bowel disease
PRA023
Flag link:
Prometheus takes on Pfizer in inflammatory bowel diseases
Prometheus takes on Pfizer in inflammatory bowel diseases
EP Vantage
Prometheus Biosciences
Pfizer
PF-06480605
PRA023
inflammatory bowel disease
Flag link:
Prometheus upsizes IPO by 33% ahead of pricing
Prometheus upsizes IPO by 33% ahead of pricing
Endpoints
Prometheus Biosciences
IPOs
Flag link:
After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard
After a slow week, the IPO train is back up and running as 3 more biotechs hop aboard
Endpoints
IPOs
Prometheus Biosciences
Longboard Pharmaceuticals
Gain Therapeutics
Flag link: